Phaseline

Companies › Nanjing Minova Pharmaceutical

Nanjing Minova Pharmaceutical: clinical trials, targets and expected readouts

2 active drug programs in 2 registered trials: 1 Phase 3, 1 Phase 1; Psychiatry, Other; next expected readout Feb 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
MI078 capsule–Phase 3Postpartum Depression (PPD)Dec 2027
MI226 injection–Phase 1Abdominal FatFeb 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07749742MI226 injectionPhase 1Abdominal FatOtherFeb 2027
NCT07721961MI078 capsulePhase 3Postpartum Depression (PPD)PsychiatryDec 2027

Targets

No annotated target.

Companies with the same targets

–

Companies built like this

Adneuris Therapeutics Syndeio Biosciences Vigonvita Life Sciences Clear Scientific Harmony Biosciences Management

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.